Our data showed that all three CRTC co-activators (CRTC1-3) are expressed at various levels in lung cancers and that CRISPR/Cas9-mediated knockouts of individual CRTCs only partially reduced the LKB1 target gene expression and had very moderate impact on lung cancer cell proliferation, colony formation, and anchorage-independent growth. The gene discussed is CALR; the disease is lung carcinoma.